查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092140

神經痛治療市場－2026-2032年全球市場預測

Neuralgia Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經痛治療市場將成長至 43.6 億美元，複合年成長率為 7.38%。

主要市場統計數據
基準年 2025 26.5億美元
預計年份：2026年 28.4億美元
預測年份 2032 43.6億美元
複合年成長率 (%) 7.38%

神經痛治療市場執行摘要

隨著慢性神經性疼痛（包括三叉神經痛、帶狀皰疹帶狀皰疹後遺症神經痛神經痛、枕神經痛、舌咽神經病變和糖尿病性神經病變病變）負擔的加重，以及醫療保健系統面臨的挑戰日益嚴峻，治療神經痛的臨床和商業性價值也日益凸顯。神經痛的特徵是突發性灼痛、刺痛或電擊樣疼痛，由神經刺激、壓迫、損傷或疾病引起。治療策略擴大結合藥物治療、微創手術、神經調控、復健護理、行為健康支持和數位化疼痛管理工具，以改善患者的功能和生活品質。臨床驗證有效的治療方法包括：用於治療三叉神經痛的抗驚厥藥物，如Carbamazepine和奧卡西平；用於治療神經病變疼痛的加巴噴丁類藥物和某些抗憂鬱症；用於局部疼痛的利多卡因和辣椒素；某些情況下可使用肉毒桿菌毒素；神經阻滯、放射線手術、射頻消融術減壓手術人口老化、糖尿病盛行率上升、帶狀Lidocaine併發症、影像技術的進步、人們對神經病變疼痛認知的提高以及多學科疼痛診所的普及，都推動了治療需求的成長。同時，疼痛治療領域正朝著實證疼痛管理的方向發展，力求最大限度地減少鴉片類藥物的使用，採用個人化的治療方案，並建立以結果為導向的護理路徑，評估疼痛強度、發作頻率、功能障礙、睡眠障礙、不利事件以及患者自述的生活品質。

神經痛治療前景的變革性轉變。

神經痛的治療正經歷著從症狀抑製到精準疼痛管理的結構性轉變。在臨床實踐中，人們越來越傾向於採用診斷演算法來區分經典的三叉神經痛（與神經血管壓迫相關）和次發性於腫瘤、多發性硬化症、創傷、糖尿病或病毒感染後神經損傷引起的神經痛，而不是僅僅依賴全身性止痛藥。高解析度磁振造影（MRI）、神經生理學檢查和標準化疼痛評估正在提高診斷的準確性並豐富治療選擇。另一個顯著的轉變是，鑑於鴉片類藥物成癮、過量、耐受性以及在許多神經病變疼痛中長期療效有限等已知的風險，人們越來越重視減少鴉片類藥物的使用。這正在加速抗驚厥藥、5-羥正腎上腺素再回收抑制劑（SNRIs）、三環抗憂鬱藥物、局部用藥、介入性疼痛療法和神經調節療法的應用。此外，醫療服務體係正日益整合，神經科醫生、神經外科醫生、疼痛專家、基層醫療醫生、牙醫、復健團隊、心理學家和藥劑師攜手合作，以減少診斷延誤，避免不必要的牙科或外科手術干預。數位健康平台、遠端監測、遠距醫療和數位化患者報告結局指標正在進一步變革後續護理，尤其適用於需要調整劑量、監測不利事件或評估長期治療效果的患者。

人工智慧對神經痛治療的累積影響

人工智慧正開始在神經痛的診斷、病患分層、臨床決策支援、藥物研發和護理協調等領域產生影響。在診斷流程中，人工智慧驅動的影像分析結合專家的觀察，可以幫助檢測神經血管壓迫、去髓鞘化病變、結構異常和術後變化。機器學習模型可以透過分析症狀說明、發作模式、藥物反應、共病和患者報告的結局，幫助識別神經病變疼痛的表現型。在治療計畫制定中，人工智慧驅動的決策支援可以幫助臨床醫生確定藥物治療的順序，識別藥物副作用高風險患者，並確定哪些患者適合轉診至神經調控療法或手術治療。人工智慧在「封閉回路型神經調控療法」中的應用也正在探索中，該療法可以根據生理訊號和疼痛回饋調整刺激參數。在藥物研發中，計算模型可以提高與神經病變疼痛相關的離子通道、發炎介質和神經修復路徑標靶辨識的準確性。然而，負責任的實施需要高度透明的演算法、高品質的訓練資料集、臨床檢驗、隱私保護、減少偏差以及明確的課責。人工智慧的整體目標並非取代臨床判斷，而是有助於及時診斷、個人化治療、提高治療依從性，並改善神經痛治療中可衡量的患者療效。

神經痛治療的關鍵區域性見解

在亞太地區，人口老化加劇、糖尿病盛行率上升、神經科醫療服務不斷擴展，以及都市區影像學檢查和介入性疼痛管理服務的可及性提高，都促使人們更加關注神經痛的治療。儘管該地區各國正在加強疼痛管理體系，但都市醫院和農村社區之間的醫療服務可近性仍存在差距。在北美，神經痛治療仍遵循主導流程，並由完善的神經內科、神經外科、疼痛醫學、復健醫學和行為醫學網路提供支援。該地區也高度重視鴉片類藥物的合理使用、保險公司的監管、電子健康記錄以及難治性神經病變疼痛的神經調控療法的引入。在拉丁美洲，隨著專科醫生培訓的改進、神經病變疼痛學名藥的普及以及對微創疼痛治療需求的成長，該地區的神經痛治療正在逐步取得進展，但醫療服務的成本效益和專科醫生分佈仍然對患者獲得醫療服務產生重大影響。在歐洲，實證處方、多學科疼痛診所、醫療技術評估和轉診途徑已高度整合，儘管各國的報銷制度和等待時間有所不同。在中東，尤其是在高所得的海灣國家，對專科醫院、醫療旅遊基礎設施和先進疼痛管理服務的投資正在推進，但全部區域的醫療服務可及性取決於醫療專業人員的配備和公共部門的能力。非洲面臨最嚴峻的醫療服務可及性挑戰，包括專科醫生覆蓋範圍有限、診斷受限、藥品獲取困難以及與其他醫療優先事項的競爭，但隨著人們對糖尿病神經神經病變、帶狀皰疹後遺症神經痛和創傷性神經痛的認知不斷提高，對擴充性的、基層醫療為基礎的神經痛治療模式的需求日益成長。

神經痛治療的主要群體分析

在東南亞國協，隨著糖尿病、老化和感染後神經病變疼痛的日益普遍，對神經痛治療的需求也不斷成長。照護模式多種多樣，從大城市先進的醫院神經科服務到資源匱乏地區以基層基層醫療主導的疼痛管理，不一而足。海灣合作理事會（GCC）國家積極投資於三級醫療機構、數位醫療基礎設施和專業的疼痛管理服務，為特定患者提供先進的診斷、介入和神經調控療法。歐盟受益於統一的監管標準、藥物安全監測系統、跨境臨床研究活動和基於指南的神經病變疼痛管理，但各成員國的報銷政策和乾預措施的可及性有所不同。在金磚國家，神經痛的治療格局複雜多樣，患者群體大規模，國家醫療基礎設施不斷完善，學名藥的可及性有所提高，但都市區地區在獲得專科醫生服務方面仍然存在持續的差距。在七國集團（G7）國家，循證臨床路徑、先進影像診斷、多學科疼痛管理計畫以及上市後安全性監測的實施總體上取得了進展，尤其注重老齡化性神經痛、糖尿病性神經病變以及減少鴉片類藥物使用的治療方法。北約成員國與歐洲和北美先進的醫療保健體係有顯著的重疊之處，完善的復健體系、豐富的軍事醫療經驗、創傷相關神經損傷的管理以及協調的專科醫療服務，都促使民用和國防醫療機構對有效的神經痛治療需求增加。

各國對神經痛治療的重點見解

在美國，透過專業的疼痛診所、先進的神經外科護理系統、鴉片類藥物風險降低措施以及在慢性疼痛護理中更多地使用患者報告結局（PROs），已建立了成熟的神經痛治療體系。在加拿大，公共資助的醫療保健、臨床指南的遵循以及多學科管理受到重視，但地區差異可能會影響專科治療的等待時間。在墨西哥，主要大都市地區的神經科和疼痛管理服務正在擴展，成本效益和保險覆蓋範圍會影響治療選擇。在巴西，糖尿病相關神經病變疼痛的負擔沉重，雖然專科護理能力正在擴大，但公立和私立醫療保健系統在服務取得方面仍存在差異。在英國，針對難治性三叉神經痛和其他神經病變疼痛，強調實證處方、階梯式治療和轉診途徑。德國利用其在神經病學、神經外科、復健和醫療設備方面的高水平專業知識，支持全面的神經痛治療。法國擁有系統化的專科醫療保健體系和藥物安全監測體系，並專注於合理使用神經病變疼痛藥物。俄羅斯在主要城市擁有完善的神經內科和神經外科醫療保健體系，但各地區的醫療服務可近性差異很大。義大利和西班牙面臨人口老化、專科醫生網路完善以及對綜合慢性疼痛治療​​需求日益成長等挑戰。在中國，隨著人口老化、糖尿病的流行以及醫療現代化進程的推進，神經內科、影像診斷和介入性疼痛管理體係正在迅速發展。在印度，由於糖尿病高發生率和人口眾多，對治療的需求非常高，而學名藥的普及、專科醫生在都市區的集中以及遠距遠端醫療的廣泛應用正在改變著治療方式。日本的特點是針對老齡化相關神經病變疼痛的先進診療路徑、強大的影像診斷能力以及對老年患者治療安全性的高度重視。在澳大利亞，以指引為基礎的神經病變疼痛治療​​得益於基層醫療和專科醫療服務之間的協作，遠端保健也改善了主要城市以外地區的就醫途徑。在韓國，先進的醫院基礎設施、數位醫療的引入以及高超的醫護人員技能相結合，為複雜神經痛病例的診斷和治療提供了有力支持。

為神經痛治療領域的領導者提供的實用建議

產業領導者應優先開發符合指引、臨床差異化、可最大限度減少鴉片類藥物使用的神經性疼痛解決方案，這些方案應能顯著改善疼痛緩解、功能、睡眠、治療連續性和生活品質。產品開發應著重於更安全的神經病變疼痛藥物療法、標靶給藥系統、局部製劑、長效干預措施以及對患者友善的神經調控技術。臨床團隊應針對整體神經性疼痛亞型（包括三叉神經痛、帶狀皰疹後遺症神經痛、糖尿病神經病變性疼痛和難治性神經病變疼痛）建立可靠的真實世界證據，同時關注對患者和保險公司至關重要的結局指標。醫療服務提供者和創新者應加強多學科診療路徑，以減少診斷延遲、避免不當治療，並促進來自基層醫療、牙科、急診醫學、神經內科、疼痛醫學和神經外科的轉診。數位化平台應支援症狀追蹤、劑量調整、不利事件監測、遠端醫療追蹤和用藥依從性監測。在新興市場，領導者應透過可擴展的醫療模式、醫護人員培訓、推廣學名藥使用以及簡化診斷流程來減輕治療的財務負擔。在所有市場，符合倫理的人工智慧應用、藥物安全監測、資料隱私保護以及全面的臨床試驗設計對於永續部署和改善患者療效至關重要。

調查方法

本執行摘要採用系統性的一手和二手調查方法編寫，重點關注檢驗的臨床、監管、流行病學和醫療服務證據。二手研究包括同行評審的醫學文獻、臨床實踐指南、藥物安全資訊、公共衛生出版物、監管文件、疾病負擔研究以及與神經痛、神經病變疼痛、介入性疼痛管理、神經調控和數位健康相關的醫療保健系統報告。一手檢驗包括來自神經病學、疼痛醫學、神經外科、藥學、復健、衛生政策以及（如適用）醫療技術領域的相關人員見解和解讀。本分析強調資料檢驗、交叉檢驗資訊來源以及排除未經證實的說法。關鍵主題從治療、病患路徑、區域可近性差異、人工智慧應用和實證醫療保健轉型等方面進行評估。本調查方法不涉及市場規模估算和預測、市場規模計算、市場佔有率分析和預測。相反，它側重於臨床相關性、推廣促進因素、獲取障礙、技術影響、監管考慮因素以及對參與神經痛治療的相關人員的戰略意義。

結論

神經痛的治療正朝著更個人化、多學科和以結果為導向的方向發展。其主要驅動力包括：精準診斷、盡可能減少鴉片類藥物使用的治療方案、早期轉診專科醫生、微創介入治療、針對頑固性疼痛的神經調控療法，以及能夠將護理延伸至門診之外的數位化工具。人工智慧 (AI) 有潛力提高診斷準確性、治療方案選擇和遠端監測，但其價值取決於嚴格的檢驗以及與臨床工作流程的合理整合。區域和國家之間的差異仍然顯著；先進的醫療保健系統已實施了全面的疼痛管理路徑，而許多新興市場仍在優先考慮醫療保健的可及性、可負擔性、醫護人員培訓以及確保診斷能力。對於行業領導者而言，未來的道路清晰明確：開發基於循證醫學的療法和技術，以改善患者在實際應用中的治療效果，融入多學科護理模式，並滿足重度神經病變疼痛患者的未滿足需求。隨著神經痛治療的不斷進步，永續的成功將取決於臨床的可靠性、安全性、公平的醫療服務取得以及生活品質的可衡量改善。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：神經痛治療市場：依治療類型分類

  • 非藥物療法
    • 針刺
    • 神經調控療法
    • 物理治療
  • 藥物治療

第8章：神經痛治療市場：依給藥方式分類

  • 注射藥物
  • 口服
  • 外用
  • 經皮給藥

第9章：神經痛治療市場：依藥物類別分類

  • 抗驚厥藥物
  • 抗憂鬱症
  • 局部麻醉劑
  • NSAIDs
  • 鴉片類藥物
  • 外用製劑

第10章 神經痛治療市場：依最終使用者分類

  • 門診手術中心
  • 家庭醫療保健
  • 醫院
  • 專科診所

第11章：神經痛治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：神經痛治療市場：依適應症分類

  • 化療引起的神經痛
  • 糖尿病神經病變
  • 帶狀皰疹後遺症神經痛
  • 三叉神經痛

第13章：神經痛治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：神經痛治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 神經痛治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boston Scientific Corporation
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr Reddys Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Johnson & Johnson
  • Medtronic plc
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-F74E250AD635

The Neuralgia Treatment Market is projected to grow by USD 4.36 billion at a CAGR of 7.38% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.65 billion
Estimated Year [2026] USD 2.84 billion
Forecast Year [2032] USD 4.36 billion
CAGR (%) 7.38%

Neuralgia Treatment Executive Summary

Neuralgia treatment is gaining clinical and commercial urgency as health systems confront the growing burden of chronic neuropathic pain, including trigeminal neuralgia, postherpetic neuralgia, occipital neuralgia, glossopharyngeal neuralgia, and diabetic neuropathic pain. Neuralgia is characterized by sudden, burning, stabbing, or electric shock-like pain caused by nerve irritation, compression, injury, or disease. Treatment strategies increasingly combine pharmacologic therapies, minimally invasive procedures, neuromodulation, rehabilitative care, behavioral health support, and digital pain management tools to improve function and quality of life. Clinically validated options include anticonvulsants such as carbamazepine and oxcarbazepine for trigeminal neuralgia, gabapentinoids and certain antidepressants for neuropathic pain, topical lidocaine or capsaicin for localized pain, botulinum toxin in selected cases, nerve blocks, radiofrequency ablation, microvascular decompression, stereotactic radiosurgery, and spinal cord or peripheral nerve stimulation where appropriate. Demand is shaped by aging populations, rising diabetes prevalence, herpes zoster complications, improved diagnostic imaging, greater recognition of neuropathic pain, and expanding access to multidisciplinary pain clinics. At the same time, the field is moving toward evidence-based opioid-sparing pain control, personalized treatment sequencing, and outcomes-focused care pathways that measure pain intensity, attack frequency, disability, sleep disruption, adverse events, and patient-reported quality of life.

Transformative Shifts in the Neuralgia Treatment Landscape

The neuralgia treatment landscape is undergoing a structural shift from symptom suppression toward precision pain management. Clinical practice is moving beyond generalized analgesic use and toward diagnosis-specific algorithms that distinguish classical trigeminal neuralgia related to neurovascular compression from secondary neuralgia caused by tumors, multiple sclerosis, trauma, diabetes, or post-viral nerve damage. High-resolution magnetic resonance imaging, neurophysiological testing, and standardized pain assessments are improving diagnostic confidence and treatment selection. Another major shift is the growing emphasis on opioid-sparing regimens due to well-documented risks of dependence, overdose, tolerance, and limited long-term efficacy in many neuropathic pain conditions. This has accelerated adoption of anticonvulsants, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, topical agents, interventional pain procedures, and neuromodulation. Care delivery is also becoming more integrated, with neurologists, neurosurgeons, pain specialists, primary care physicians, dentists, rehabilitation teams, psychologists, and pharmacists collaborating to reduce delays in diagnosis and avoid unnecessary dental or surgical interventions. Digital health platforms, remote monitoring, teleconsultations, and electronic patient-reported outcome measures are further reshaping follow-up care, especially for patients requiring dose titration, adverse-event monitoring, or long-term procedural assessment.

Cumulative Impact of Artificial Intelligence on Neuralgia Treatment

Artificial intelligence is beginning to influence neuralgia treatment across diagnosis, patient stratification, clinical decision support, drug discovery, and care coordination. In diagnostic workflows, AI-enabled imaging analysis can support the detection of neurovascular compression, demyelinating lesions, structural abnormalities, and post-surgical changes when used alongside specialist interpretation. Machine learning models can help identify neuropathic pain phenotypes by analyzing symptom descriptions, attack patterns, medication responses, comorbidities, and patient-reported outcomes. In treatment planning, AI-driven decision support may assist clinicians in sequencing pharmacologic therapy, identifying patients at higher risk of adverse drug reactions, and recognizing candidates for neuromodulation or surgical referral. AI is also being explored for closed-loop neuromodulation, where stimulation parameters may be adjusted based on physiologic signals and pain-related feedback. In pharmaceutical research, computational models can improve target identification for ion channels, inflammatory mediators, and nerve repair pathways relevant to neuropathic pain. However, responsible deployment requires transparent algorithms, high-quality training datasets, clinical validation, privacy protection, bias mitigation, and clear accountability. The cumulative impact of AI is not the replacement of clinical judgment, but the enhancement of timely diagnosis, personalized therapy, treatment adherence, and measurable patient outcomes in neuralgia care.

Key Regional Insights for Neuralgia Treatment

Asia-Pacific is experiencing rising attention to neuralgia treatment due to population aging, increasing diabetes prevalence, expanding neurology services, and broader access to imaging and interventional pain care in urban centers. Countries across the region are strengthening pain management capacity, although access remains uneven between metropolitan hospitals and rural communities. North America remains a highly protocol-driven environment for neuralgia treatment, supported by established neurology, neurosurgery, pain medicine, rehabilitation, and behavioral health networks. The region also places strong emphasis on opioid stewardship, payer scrutiny, electronic health records, and adoption of neuromodulation for refractory neuropathic pain. Latin America is advancing gradually, with improved specialist training, broader availability of generic neuropathic pain medicines, and growing demand for minimally invasive pain procedures, while affordability and specialist distribution continue to shape access. Europe shows strong integration of evidence-based prescribing, multidisciplinary pain clinics, health technology assessment, and surgical referral pathways, with variation across countries in reimbursement and waiting times. The Middle East is investing in specialist hospitals, medical tourism infrastructure, and advanced pain management services, particularly in high-income Gulf markets, while broader regional access is influenced by workforce availability and public-sector capacity. Africa faces the greatest access challenges, including limited specialist coverage, diagnostic constraints, medicine availability gaps, and competing healthcare priorities, yet rising awareness of diabetic neuropathy, postherpetic neuralgia, and trauma-related nerve pain is increasing the need for scalable, primary-care-integrated neuralgia treatment models.

Key Group Insights for Neuralgia Treatment

ASEAN countries are seeing increasing need for neuralgia treatment as diabetes, aging, and post-infectious neuropathic pain become more prominent, with care models ranging from advanced hospital-based neurology services in major cities to primary-care-led pain management in resource-constrained settings. The GCC is characterized by strong investment in tertiary hospitals, digital health infrastructure, and specialist pain services, supporting access to advanced diagnostics, interventional procedures, and neuromodulation for selected patients. The European Union benefits from harmonized regulatory standards, pharmacovigilance systems, cross-border clinical research activity, and guideline-oriented neuropathic pain management, although reimbursement policies and access to interventional care vary by member state. BRICS countries represent diverse neuralgia treatment conditions, combining large patient populations, expanding domestic healthcare infrastructure, increasing generic medicine availability, and persistent disparities in specialist access between urban and rural areas. G7 countries generally demonstrate higher adoption of evidence-based clinical pathways, advanced imaging, multidisciplinary pain programs, and post-market safety monitoring, with particular focus on aging-related neuralgia, diabetic neuropathy, and opioid-sparing care. NATO member countries overlap significantly with advanced European and North American healthcare systems, where rehabilitation readiness, military medicine experience, trauma-related nerve injury management, and coordinated specialty care contribute to demand for effective neuralgia treatment across civilian and defense healthcare settings.

Key Country Insights for Neuralgia Treatment

The United States has a mature neuralgia treatment environment shaped by specialty pain clinics, advanced neurosurgical capabilities, opioid-risk mitigation policies, and growing use of patient-reported outcomes in chronic pain care. Canada emphasizes publicly funded access, clinical guideline adherence, and multidisciplinary management, though regional variation can affect wait times for specialty procedures. Mexico is expanding access to neurologic and pain management services in major urban centers, with affordability and insurance coverage influencing treatment selection. Brazil has a large burden of diabetes-related neuropathic pain and expanding specialty care capacity, while access differs across public and private systems. The United Kingdom emphasizes evidence-based prescribing, stepped care, and referral pathways for refractory trigeminal neuralgia and other neuropathic pain conditions. Germany benefits from strong neurology, neurosurgery, rehabilitation, and medical device expertise, supporting comprehensive neuralgia treatment. France maintains structured specialist care and pharmacovigilance systems, with attention to appropriate use of neuropathic pain medicines. Russia faces broad geographic variation in access while maintaining significant neurology and neurosurgical capacity in major cities. Italy and Spain combine aging populations, established specialist networks, and demand for integrated chronic pain care. China is rapidly expanding neurology, imaging, and interventional pain capacity, driven by aging, diabetes, and healthcare modernization. India faces high need due to diabetes prevalence and large population scale, with treatment shaped by access to generics, specialist concentration in cities, and growing telemedicine use. Japan has advanced care pathways for aging-related neuropathic pain, strong imaging capabilities, and high attention to treatment safety in older adults. Australia supports guideline-based neuropathic pain treatment through integrated primary and specialist care, with telehealth improving access outside major cities. South Korea combines advanced hospital infrastructure, digital health adoption, and high procedural capability, supporting diagnosis and treatment of complex neuralgia cases.

Actionable Recommendations for Neuralgia Treatment Leaders

Industry leaders should prioritize clinically differentiated, opioid-sparing neuralgia treatment solutions that align with guideline-based care and demonstrate measurable improvements in pain relief, function, sleep, treatment persistence, and quality of life. Product development should focus on safer neuropathic pain pharmacotherapies, targeted delivery systems, topical formulations, longer-lasting interventional approaches, and patient-friendly neuromodulation technologies. Clinical teams should generate robust real-world evidence across neuralgia subtypes, including trigeminal neuralgia, postherpetic neuralgia, diabetic neuropathic pain, and procedure-resistant neuropathic pain, while capturing outcomes that matter to patients and payers. Healthcare providers and innovators should strengthen multidisciplinary care pathways that reduce diagnostic delays, avoid inappropriate treatment, and streamline referral from primary care, dentistry, emergency medicine, neurology, pain medicine, and neurosurgery. Digital platforms should support symptom tracking, medication titration, adverse-event surveillance, telehealth follow-up, and adherence monitoring. In emerging markets, leaders should improve affordability through scalable care models, clinician education, generic access, and simplified diagnostic protocols. Across all markets, ethical AI deployment, pharmacovigilance, data privacy, and inclusive clinical trial design will be essential for sustainable adoption and improved patient outcomes.

Research Methodology

This executive summary is developed through a structured secondary and primary research methodology focused on verified clinical, regulatory, epidemiological, and healthcare delivery evidence. Secondary research includes peer-reviewed medical literature, clinical practice guidelines, drug safety communications, public health publications, regulatory documents, disease burden studies, and health system reports related to neuralgia, neuropathic pain, interventional pain management, neuromodulation, and digital health. Primary validation includes expert-informed interpretation from stakeholders across neurology, pain medicine, neurosurgery, pharmacy, rehabilitation, health policy, and healthcare technology where applicable. The analysis emphasizes data triangulation, cross-source validation, and exclusion of unsupported claims. Key themes are assessed across treatment modalities, patient pathways, regional access differences, AI applications, and evidence-based care transformation. The methodology avoids market estimation, market sizing, market share analysis, and forecasting, focusing instead on clinical relevance, adoption drivers, access barriers, technology impact, regulatory considerations, and strategic implications for stakeholders in neuralgia treatment.

Conclusion

Neuralgia treatment is evolving into a more personalized, multidisciplinary, and outcomes-driven field. The strongest momentum is centered on accurate diagnosis, opioid-sparing therapy, earlier specialist referral, minimally invasive intervention, neuromodulation for refractory pain, and digital tools that extend care beyond clinic visits. Artificial intelligence has the potential to improve diagnostic precision, treatment selection, and remote monitoring, but its value depends on rigorous validation and responsible integration into clinical workflows. Regional and country-level differences remain substantial, with advanced health systems adopting comprehensive pain pathways while many emerging markets continue to prioritize access, affordability, workforce training, and diagnostic capacity. For industry leaders, the path forward is clear: build evidence-backed therapies and technologies that improve real-world patient outcomes, fit into multidisciplinary care models, and address the unmet needs of patients living with severe neuropathic pain. As neuralgia care advances, sustainable success will depend on clinical credibility, safety, equitable access, and measurable improvements in quality of life.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuralgia Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Non Pharmacological
    • 7.2.1. Acupuncture
    • 7.2.2. Neuromodulation
    • 7.2.3. Physical Therapy
  • 7.3. Pharmacological

8. Neuralgia Treatment Market, by Delivery Mode

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical
  • 8.5. Transdermal

9. Neuralgia Treatment Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Anticonvulsants
  • 9.3. Antidepressants
  • 9.4. Local Anesthetics
  • 9.5. NSAIDs
  • 9.6. Opioids
  • 9.7. Topical Agents

10. Neuralgia Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Home Healthcare
  • 10.4. Hospitals
  • 10.5. Specialty Clinics

11. Neuralgia Treatment Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Neuralgia Treatment Market, by Indication

  • 12.1. Introduction
  • 12.2. Chemotherapy Induced Neuralgia
  • 12.3. Diabetic Neuropathy
  • 12.4. Postherpetic Neuralgia
  • 12.5. Trigeminal Neuralgia

13. Neuralgia Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Neuralgia Treatment Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Neuralgia Treatment Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. AbbVie Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Biogen, Inc.
  • 17.5. Boston Scientific Corporation
  • 17.6. Bristol Myers Squibb
  • 17.7. Cipla Limited
  • 17.8. Dr Reddys Laboratories Ltd
  • 17.9. Eli Lilly and Company
  • 17.10. GlaxoSmithKline plc
  • 17.11. Grunenthal GmbH
  • 17.12. Johnson & Johnson
  • 17.13. Medtronic plc
  • 17.14. Merz Pharma GmbH & Co. KGaA
  • 17.15. Novartis AG
  • 17.16. Pfizer Inc.
  • 17.17. Sanofi S.A.
  • 17.18. Sun Pharmaceutical Industries Ltd.
  • 17.19. Teva Pharmaceutical Industries Ltd.
  • 17.20. UCB SA
  • 17.21. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEURALGIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEURALGIA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEURALGIA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEURALGIA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NEURALGIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUPUNCTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUPUNCTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUPUNCTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NSAIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NSAIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOPICAL AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TOPICAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMOTHERAPY INDUCED NEURALGIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHEMOTHERAPY INDUCED NEURALGIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMOTHERAPY INDUCED NEURALGIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POSTHERPETIC NEURALGIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POSTHERPETIC NEURALGIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POSTHERPETIC NEURALGIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TRIGEMINAL NEURALGIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRIGEMINAL NEURALGIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TRIGEMINAL NEURALGIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. NATO NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. NATO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. NATO NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NATO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. G7 NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. G7 NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. G7 NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. G7 NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. INDIA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. INDIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. INDIA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 213. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. INDIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 293. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. GLOBAL NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 307. GLOBAL NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025